References
- Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. PMID: 29496507. doi:10.1016/j.diabres.2018.02.023
- Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. PMID: 25555821. doi:10.1136/bmj.g7607
- Huang SF, Zhang YF, Kang MX, et al. Research progress on pathogenesis and markers of pancreatic cancer-related diabetes. Chin J General Surg. 2018;33(6):531–533. Chinese.
- Tang Y, Sun Q, Yang J, et al. Tumor markers changes among different blood glucose level people. Chin J Gerontol. 2018;38(24):5923–5926.
- Diabetes Branch of Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes in China (2017). Chin J Diabetes. 2018;10(1):4–67. Chinese.
- Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. PMID: 32345662; PMCID: PMC7186854. doi:10.1136/bmj.m997
- Yang J, Ren B, Yang G, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. 2020;77(2):305–321. PMID: 31432232. doi:10.1007/s00018-019-03278-z
- Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15. PMID: 29195904; PMCID: PMC5805864. doi:10.1016/S2213-8587(17)30366-2
- Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8(1):2732. doi:10.1038/s41598-018-21048-y
- Chen YB, Zhang W, Wang WN, Lin ZZ. A study of serum CA199 levels in relation to glycemic control levels and age in patients with type 2 diabetes. Lab Med. 2020;38(1):68–70. Chinese.
- Zhang F, Bao Y, Zhou J, et al. Serum ca19-9 level in diabetic patients and its relationship with pancreatic disease. Chin J New Drugs Clin Pract. 2011;2012(6):431–435.
- Du ZX, Liang MM, Sun J, Wang WJ, Liu YH, Yang JH. Clinical significance of serum CA-125, CA19-9 and CEA in pulmonary tuberculosis with and without type 2 diabetes. Tuberculosis. 2017;107:104–110. PMID: 29050756. doi:10.1016/j.tube.2017.08.006
- Zhang DD, Tang X, Jin DY, Hu YH, Gao P. 中国成年人糖尿病患病率Meta分析. [Prevalence of diabetes in Chinese adults: a meta-analysis]. Zhonghua Liu Xing Bing Xue Za Zhi. 2018. 39(6):852–857. Chinese. PMID: 29936760. doi:10.3760/cma.j.issn.0254-6450.2018.06.030
- Shang X, Song C, Du X, Shao H, Xu D, Wang X. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. Saudi Med J. 2017;38(2):204–208. PMID: 28133696; PMCID: PMC5329635. doi:10.15537/smj.2017.2.15649
- Yu H, Li R, Zhang L, Chen H, Bao Y, Jia W. Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients. Exp Diabetes Res. 2012;2012:745189. PMID: 22778715; PMCID: PMC3384953. doi:10.1155/2012/745189
- Shang XJ, Du XM, Fang T, Zhang R, Tian FS. 2型糖尿病患者铁超载对肿瘤标志物CA199水平的影响. [Effect of iron overload on the level of carbohydrate antigen 199 in type 2 diabetes mellitus]. Zhonghua Yi Xue Za Zhi. 2019. 99(22):1722–1726. Chinese. PMID: 31216819. doi:10.3760/cma.j.issn.0376-2491.2019.22.008
- Lu B, Fang LN, Zhong S. Correlation between serum CA199 level and glycemic control in patients with type 2 diabetes mellitus. J Bengbu Med Coll. 2012;37(12):1479–1481.